Methods for Enhancing Efficacy of Therapeutic Immune Cells
AssigneeNational University of Singapore
InventorsDario Campana, Takahiro Kamiya
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of using a receptor (e.g., chimeric antigen receptor—CAR) that activates an immune response upon binding a cancer cell ligand in conjunction with a target-binding molecule that targets a protein or molecule CI for removal or neutralization to generate enhanced anti-cancer immune cells. The present invention also relates to engineered immune cells having enhanced therapeutic efficacy and uses thereof.
Claims22
An engineered immune cell that comprises a nucleic acid comprising a nucleotide sequence encoding an immune activating receptor and a nucleic acid comprising a nucleotide sequence encoding a target-binding molecule linked to a localizing domain.
Dependencies are inferred from the claim text.